Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: Cross-sectional analysis of a multisite retrospective cohort study

Clinical Infectious Diseases

Volumn 60, Issue 8, 2015, Pages 1145-1152

  Smith, Bryce D ^a   Yartel, Anthony K ^a   Krauskopf, Katherine ^b   Massoud, Omar I ^c   Brown, Kimberly A ^d   Fallon, Michael B ^e   Rein, David B ^f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

anti HCV prevalence; HCV testing; hepatitis C virus (HCV); outpatient primary care; predictors of HCV positivity

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; FEMALE; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTPATIENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84964204539     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ002     Document Type: Article

References (40)

1. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160:293-300.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31:1090-101.
3. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43:66-72.
4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-21, 521.e1-6.
5. Centers for Disease Control and Prevention. Viral hepatitis surveillance, United States, 2011. Available at: http://www.cdc.gov/hepatitis/ Statistics/2011Surveillance/PDFs/2011HepSurveillanceRpt.pdf. Accessed 15 September 2014.
6. Poynard T. Hepatitis C: natural history, biology, treatment monitoring [in French]. Pathol Biol (Paris) 1999; 47:911-6.
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-93.
8. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
9. Vaidya A, Perry CM. Simeprevir: first global approval. Drugs 2013; 73:2093-106.
10. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19):1-39.
11. A1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep 1999; 48(RR-10): 1-59, 61-6.
12. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care 2011; 17:548-55.
13. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012; 55: 1047-55.
14. Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011; 18:474-81.
15. Trooskin SB, Navarro VJ, Winn RJ, et al. Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 2007; 13:1074-8.
16. Almario CV, Vega M, Trooskin SB, Navarro VJ. Examining hepatitis C virus testing practices in primary care clinics. J Viral Hepat 2012; 19: e163-9.
17. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61(RR-4):1-32.
18. Smith BD, Yartel AK. Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med 2014; 47:233-41.
19. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis 2013; 56:40-50.
20. Moyer VA, Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159:349-57.
21. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14.
22. Janssen KJM, Donders ART, Harrell FE, et al. Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol 2010; 63:721-7.
23. Raghunathan T. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 2001; 27:79-90.
24. Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputation. Biometrika 1999; 86:948-55.
25. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. New York: Cambridge University Press, 2007.
26. Bornschlegel K, Berger M, Garg RK, et al. Prevalence of hepatitis C infection in New York City, 2004. J Urban Health 2009; 86:909-17.
27. New York City Department of Health and Mental Hygiene. Hepatitis A, B, and C surveillance reports. Available at: http://www.nyc.gov/html/ doh/downloads/pdf/cd/cd-hepabc-surveillance-report-08-09.pdf. Accessed 29 April 2014.
28. Houston Department of Health and Human Services. Study examines local hepatitis C prevalence. Texas Medical Center News. Available at: http://www.tmc.edu/tmcnews/01-15-02/page-21.html. Accessed 29 April 2014.
29. Hall MR, Ray D, Payne JA. Prevalence of hepatitis C, hepatitis B, and human immunodeficiency virus in a Grand Rapids, Michigan emergency department. J Emerg Med 2010; 38:401-5.
30. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birthcohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263-70.
31. Torrone EA, Thomas JC, Maman S, et al. Risk behavior disclosure during HIV test counseling. AIDS Patient Care STDS 2010; 24:551-61.
32. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40(suppl 5):S276-85.
33. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010; 24:753-62.
34. Batki S, Sorensen J. Care of injection drug users with HIV. In: Cohen PT, Sande MA, Volberding P. The AIDS knowledge base: a textbook on HIV disease from the University of California, San Francisco and San Francisco General Hospital. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins, 1999.
35. O'Brien SF, Xi G, Yi QL, Goldman M. Understanding non-disclosure of deferrable risk: a study of blood donors with a history of intravenous drug use. Transfus Med 2010; 20:15-21.
36. Shapiro S, Castellana JV, Sprafka JM. Alcohol-containing mouthwashes and oropharyngeal cancer: a spurious association due to underascertainment of confounders?. Am J Epidemiol 1996; 144:1091-5.
37. Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models. Am Stat 2007; 61:79-90.
38. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002; 7:147-77.
39. Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mir HM. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37:703-9.
40. McMahon BJ, Bruden D, Bruce MG, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology 2010; 138:922-31.e1.